Von Willebrand Disease Market: Insights into Epidemiology, Treatment Landscape, and Key Players | DelveInsight | Band Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corp

The Von Willebrand Disease Market Size in the United States was estimated to be more than USD 350 million in 2023.

Emerging therapies for Von Willebrand disease, including WILATE, VONVENDI, VGA039, Efanesoctocog alfa (BIVV001), and others, are anticipated to drive significant growth in the Von Willebrand disease market in the coming years.

DelveInsight has released a new report, "Von Willebrand Disease - Market Insights, Epidemiology, and Market Forecast-2034", providing comprehensive insights into the disease, historical and projected epidemiology, and market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Von willebrand disease market report @ https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Von willebrand disease Market Report:

*
The Von Willebrand Disease (VWD) market in the United States was valued at over USD 350 million in 2023 and is projected to expand between 2024 and 2034, fueled by a growing number of diagnosed cases and advancements in recombinant therapies. Leading companies in this space include CSL Behring, LFB Biomedicaments SA, Octapharma AG, and Grifols SA.

*
Market dynamics are expected to shift with better diagnostic techniques, heightened disease awareness, and rising global healthcare expenditures. However, most therapies in the pipeline remain in early development, with players such as Vega Therapeutics and Sanofi actively advancing new candidates.

*
Notable regulatory updates include the FDA's December 2023 expanded approval of WILATE as the first von Willebrand factor (VWF) concentrate for prophylactic use in all VWD types, and the May 2023 Orphan Drug Designation granted to VGA039. Similarly, the expanded use of VONVENDI (BAX 111) for prophylactic and pediatric treatment is poised to significantly influence the US market, following its earlier FDA approval in 2018 for perioperative bleeding management.

*
Scientific advancements, such as cryo-electron microscopy studies of the BIVV001 complex, have provided deeper insights into FVIII and VWF interactions, crucial for clot formation. Disruptions in these interactions, particularly VWF DD3 domain mutations, underpin VWD type 2N.

*
In 2023, approximately 13,000 diagnosed VWD cases were reported in the US, with females comprising around 55% (over 7,000 cases). These numbers are expected to rise steadily through 2034.

*
In January 2025, Star Therapeutics secured FDA Fast Track designation for its investigational monoclonal antibody VGA039, potentially the first subcutaneous therapy addressing all VWD types with a more convenient dosing regimen.

*
Several companies, including Band Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corporation, Sanofi, and others, are actively pursuing novel therapies. Prominent emerging options include WILATE, VONVENDI, VGA039, and Efanesoctocog alfa (BIVV001), which are expected to reshape the treatment landscape in the coming years.

Von willebrand disease Overview

Von Willebrand disease (VWD) is a hereditary bleeding disorder resulting from either a deficiency or malfunction of von Willebrand factor (VWF), a key protein involved in blood clotting. VWF plays a vital role by binding factor VIII and platelets to the vessel wall, facilitating the formation of a platelet plug. The condition is heterogeneous and is broadly categorized into inherited and acquired forms.

Diagnosis typically requires a series of blood tests, including assessments of VWF antigen levels, clotting time, clot formation capability, and platelet function.

DelveInsight's Von Willebrand Disease market report provides detailed insights into the disorder's pathophysiology, diagnostic approaches, and treatment options, while also mapping the real-world patient journey from the onset of symptoms to diagnosis and therapy.

Von willebrand disease Market Outlook

In the United States, the therapeutic landscape for Von Willebrand Disease (VWD) is divided into three main categories.

*
Non-replacement therapy: Desmopressin (DDAVP) is used to raise plasma levels of von Willebrand factor (VWF) and is generally prescribed for mild cases.

*
Replacement therapy: Plasma-derived factor concentrates, including HUMATE-P (CSL Behring), ALPHANATE (Grifols), IMMUNATE, and WILATE (Octapharma), are administered to directly restore deficient VWF.

*
Adjunct therapy: Antifibrinolytics such as tranexamic acid (CYCLOKAPRON) help stabilize clots by preventing premature breakdown.

A recent advancement within replacement therapy is VONVENDI, a recombinant VWF concentrate that provides an alternative to plasma-based products. For severe cases-particularly Type 2 and Type 3 VWD or major bleeding events-virally inactivated factor VIII concentrates containing VWF have proven to be more effective second-line options when standard treatments fall short.

Looking ahead, several pharmaceutical companies, including Sanofi, Octapharma, Vega Therapeutics, and others, are actively advancing novel therapies in clinical trials. These pipeline treatments are designed to enhance efficacy, safety, and patient convenience, potentially reshaping the VWD treatment landscape in the coming years.

Discover how the Von willebrand disease market is rising in the coming years @ https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Von willebrand disease Marketed Drugs

*
WILATE: OctaPharma

*
VONVENDI: Takeda Pharmaceuticals

Von willebrand disease Emerging Drugs

*
VGA039: Vega Therapeutics

*
Efanesoctocog alfa (BIVV001): Sanofi

Scope of the Von willebrand disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Von willebrand disease Companies: Band Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corporation, Sanofi, and others

*
Key Von willebrand disease Therapies: WILATE, VONVENDI, VGA039, Efanesoctocog alfa (BIVV001), and others

*
Von willebrand disease Therapeutic Assessment: Von willebrand disease current marketed and Von willebrand disease emerging therapies

*
Von willebrand disease Market Dynamics: Von willebrand disease market drivers and Von willebrand disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Von willebrand disease Unmet Needs, KOL's views, Analyst's views, Von willebrand disease Market Access and Reimbursement

To know what's more in our Von willebrand disease report, visit https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Von willebrand disease Market Report:

*
Von willebrand disease market report covers a descriptive overview and comprehensive insight of the Von willebrand disease Epidemiology and Von willebrand disease market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Von willebrand disease market report provides insights into the current and emerging therapies.

*
The Von willebrand disease market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Von willebrand disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Von willebrand disease market.

Got queries? Click here to know more about the Von willebrand disease market Landscape [https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Von willebrand disease Patient Share (%) Overview at a Glance

5. Von willebrand disease Market Overview at a Glance

6. Von willebrand disease Disease Background and Overview

7. Von willebrand disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Von willebrand disease

9. Von willebrand disease Current Treatment and Medical Practices

10. Unmet Needs

11. Von willebrand disease Emerging Therapies

12. Von willebrand disease Market Outlook

13. Country-Wise Von willebrand disease Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Von willebrand disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Von willebrand disease Market Outlook 2034 [https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Von willebrand disease Pipeline Insights, DelveInsight

"Von willebrand disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Von willebrand disease market. A detailed picture of the Von willebrand disease pipeline landscape is provided, which includes the disease overview and Von willebrand disease treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=von-willebrand-disease-market-insights-into-epidemiology-treatment-landscape-and-key-players-delveinsight-band-therapeutics-tagcyx-biotechnologies-china-biologic-products-thrombotargets-corp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.